Collateral License Agreement between GeneLink, Inc. and The University of North Texas Health Science Center at Forth Worth dated July 1, 1996. 2 pages
The Wake North Carolina Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center is a comprehensive legal agreement that outlines the terms and conditions of collaboration between both parties in the field of genetic research and development. This agreement aims to protect the intellectual property and proprietary rights of each entity while promoting the advancement of scientific knowledge for the benefit of society. The agreement covers various aspects including the licensing of specific genetic technologies, research sharing, commercialization rights, and financial terms. Under this Collateral License Agreement, Gentling, Inc. and The University of North Texas Health Science Center commit to a mutually beneficial relationship wherein they can collaborate on specific projects, share resources, and leverage their respective expertise. Through this agreement, both parties can grant each other licenses to use their copyrighted and patented technologies, ensuring a fair and equal exchange of knowledge and resources. The Wake North Carolina Collateral License Agreement encompasses several types of collaborations and licenses, tailored to the specific needs and goals of Gentling, Inc. and The University of North Texas Health Science Center. These may include: 1. Research Collaboration Licenses: This type of license allows both parties to collaborate on specific research projects by sharing data, materials, and resources. It enables the exchange of valuable information and fosters scientific progress in the field of genetics. 2. Patent Licensing: In cases where either Gentling, Inc. or The University of North Texas Health Science Center owns patented genetic technologies, this agreement allows for the licensing of these patents to the other party. This facilitates the usage and commercialization of patented technologies for mutual benefit. 3. Commercialization Rights: In certain circumstances, this agreement outlines the terms and conditions for commercializing any breakthrough genetic technologies or products resulting from the collaboration. It provides guidelines for revenue sharing, royalties, and any potential future partnerships or licensing agreements. 4. Financial Terms: The Wake North Carolina Collateral License Agreement includes provisions for financial considerations and responsibilities between Gentling, Inc. and The University of North Texas Health Science Center. This includes the payment of licensing fees, research funding, and any other financial obligations agreed upon by both parties. In conclusion, the Wake North Carolina Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center serves as a framework for collaboration, technology licensing, and research sharing in the field of genetics. It enables both entities to leverage their resources, protect their intellectual property, and foster scientific advancements that can have a positive impact on healthcare and society as a whole.
The Wake North Carolina Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center is a comprehensive legal agreement that outlines the terms and conditions of collaboration between both parties in the field of genetic research and development. This agreement aims to protect the intellectual property and proprietary rights of each entity while promoting the advancement of scientific knowledge for the benefit of society. The agreement covers various aspects including the licensing of specific genetic technologies, research sharing, commercialization rights, and financial terms. Under this Collateral License Agreement, Gentling, Inc. and The University of North Texas Health Science Center commit to a mutually beneficial relationship wherein they can collaborate on specific projects, share resources, and leverage their respective expertise. Through this agreement, both parties can grant each other licenses to use their copyrighted and patented technologies, ensuring a fair and equal exchange of knowledge and resources. The Wake North Carolina Collateral License Agreement encompasses several types of collaborations and licenses, tailored to the specific needs and goals of Gentling, Inc. and The University of North Texas Health Science Center. These may include: 1. Research Collaboration Licenses: This type of license allows both parties to collaborate on specific research projects by sharing data, materials, and resources. It enables the exchange of valuable information and fosters scientific progress in the field of genetics. 2. Patent Licensing: In cases where either Gentling, Inc. or The University of North Texas Health Science Center owns patented genetic technologies, this agreement allows for the licensing of these patents to the other party. This facilitates the usage and commercialization of patented technologies for mutual benefit. 3. Commercialization Rights: In certain circumstances, this agreement outlines the terms and conditions for commercializing any breakthrough genetic technologies or products resulting from the collaboration. It provides guidelines for revenue sharing, royalties, and any potential future partnerships or licensing agreements. 4. Financial Terms: The Wake North Carolina Collateral License Agreement includes provisions for financial considerations and responsibilities between Gentling, Inc. and The University of North Texas Health Science Center. This includes the payment of licensing fees, research funding, and any other financial obligations agreed upon by both parties. In conclusion, the Wake North Carolina Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center serves as a framework for collaboration, technology licensing, and research sharing in the field of genetics. It enables both entities to leverage their resources, protect their intellectual property, and foster scientific advancements that can have a positive impact on healthcare and society as a whole.